Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Receivables (2024 - 2025)

Syndax Pharmaceuticals has reported Change in Receivables over the past 2 years, most recently at $30.4 million for Q4 2025.

  • Quarterly results put Change in Receivables at $30.4 million for Q4 2025, up 735.27% from a year ago — trailing twelve months through Dec 2025 was $30.4 million (up 736.15% YoY), and the annual figure for FY2025 was $30.4 million, up 736.15%.
  • Change in Receivables for Q4 2025 was $30.4 million at Syndax Pharmaceuticals, up from -$11.8 million in the prior quarter.
  • Over the last five years, Change in Receivables for SNDX hit a ceiling of $30.4 million in Q4 2025 and a floor of -$11.8 million in Q3 2025.